With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY ... below the mean price target of $988.61. The Street-high price target of $1,190 implies a modest ...

Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Wall Street saw slight gains on Thursday with positive earnings from major companies such as Eli Lilly and Tapestry. Despite ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Wall Street was poised for a flat start as investors analyzed earnings from major companies like Honeywell and anticipated ...

Eli Lilly's (LLY) fourth quarter and full-year earnings mostly met Wall Street estimates but missed expectations for sales of its weight loss GLP-1 drugs Mounjaro and Zepbound.

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly’s profit doubled in the fourth quarter ... easily topping the $5.01 that Wall Street was looking for, according to a poll of industry analysts by FactSet. Mounjaro and Zepbound ...